lisocabtagene maraleucel

lisocabtagene maraleucel

  • January 2019 •
  • 30 pages •
  • Report ID: 5780225 •
  • Format: PDF
Drug Overview
Lisocabtagene maraleucel (also known as JCAR017; Celgene) will be the third autologous chimeric antigen receptor T-cell (CAR-T) therapy to reach the diffuse large B-cell lymphoma (DLBCL) market following the launches of approved CAR-T drugs Kymriah (tisagenlecleucel; Novartis) and Yescarta (axicabtagene ciloleucel; Gilead). Lisocabtagene maraleucel has demonstrated comparable efficacy to Kymriah and Yescarta and a positive tolerability profile in the Phase I TRANSCEND trial (ClinicalTrials.gov identifier: NCT02631044) in relapsed/refractory DLBCL patients. These results will help lisocabtagene maraleucel to compete with the approved CAR-T therapies, as well as several pipeline regimens targeting relapsed/refractory patients.
Lisocabtagene maraleucel is an autologous T-cell therapy genetically engineered to express a CAR targeting cluster of differentiation (CD)19. CD19 is only expressed on B cells, thus it is an attractive target in B-cell leukemias and B-cell lymphomas. Studies suggest CD19 CAR-T cell-based immunotherapies effectively recognize and kill CD19-positive target cells and result in a high clinical response rate in the treatment of refractory B-cell malignancies, including DLBCL.

Analyst Outlook
Lisocabtagene maraleucel (also known as JCAR017; Celgene) will be the third autologous chimeric antigen receptor T-cell (CAR-T) therapy to reach the diffuse large B-cell lymphoma (DLBCL) market following the launches of approved CAR-T drugs Kymriah (tisagenlecleucel; Novartis) and Yescarta (axicabtagene ciloleucel; Gilead). Lisocabtagene maraleucel has demonstrated comparable efficacy to Kymriah and Yescarta and a positive tolerability profile in the Phase I TRANSCEND trial (ClinicalTrials.gov identifier:NCT02631044) in relapsed/refractory DLBCL patients. These results will help lisocabtagene maraleucel to compete with the approved CAR-T therapies, as well as several pipeline regimens targeting relapsed/refractory patients.